Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis

Key Points

• Long-term routine laboratory toxicity monitoring improves safety during DMARD treatment.
• Data scarcity on monitoring practices necessitates frequent laboratory tests in clinical settings.
• The analysis underscores the importance of routine monitoring to mitigate risks of adverse effects.
• Implementation of effective monitoring strategies may enhance patient outcomes in rheumatoid arthritis.